According to studies presented at the World Congress on Antimicrobial Agents, held in Chicago, United States, starting in mid-year beginning to be marketed the flu vaccine in the form of nasal spray in that country.
Marketed only in Switzerland since October 2000, the new vaccine called ‘Nasal flu’ just is compared with the vaccine injection in 240 people, 110 of them over 60 years. In terms of efficiency, responded to all the criteria of the European authority’s taxes to the vaccine by intramuscular injection.

The vaccine with spray revealed have even an advantage on the vaccine injection: because of its mode of administration, causes in the nostrils a strong response of the agency against the virus. This effect supplementary to the vaccine of nasal spray prevents the multiplication of the virus in the nose and throat, which would avoid the contaminations of people living or working in the environment of the patient, affected mainly by the projections of the virus during the sneezing.